Cytosorbents (NASDAQ:CTSO) Earns Buy Rating from D. Boral Capital

Cytosorbents (NASDAQ:CTSO)‘s stock had its “buy” rating reiterated by equities research analysts at D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They presently have a $10.00 target price on the medical research company’s stock.

Several other research analysts have also recently issued reports on the stock. StockNews.com assumed coverage on shares of Cytosorbents in a report on Saturday, February 22nd. They issued a “hold” rating on the stock. HC Wainwright reissued a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a research report on Monday, November 11th. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Stock Up 0.9 %

Shares of NASDAQ:CTSO opened at $1.10 on Tuesday. The firm has a market capitalization of $60.15 million, a PE ratio of -3.06 and a beta of 0.61. The firm has a fifty day moving average of $1.03 and a 200 day moving average of $1.04. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. Cytosorbents has a 52-week low of $0.70 and a 52-week high of $1.61.

Hedge Funds Weigh In On Cytosorbents

Several hedge funds have recently modified their holdings of CTSO. Millennium Management LLC bought a new position in shares of Cytosorbents during the 4th quarter valued at approximately $30,000. Renaissance Technologies LLC boosted its stake in Cytosorbents by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock valued at $80,000 after acquiring an additional 8,400 shares in the last quarter. Northern Trust Corp boosted its holdings in Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock worth $83,000 after acquiring an additional 16,701 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Cytosorbents in the 4th quarter valued at $99,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares during the period. Hedge funds and other institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.